OBJECTIVE: To systematically evaluate the efficacy and safety of linezolid combined with conventional antitubercular agents in the treatment of drug-resistant tuberculosis. METHODS: Randomized controlled trials（the control group was given conventional antitubercular agents

while the observation group was treated with linezolid based on the control group） on linezolid in the treatment of drug-resistant tuberculosis were retrieved from PubMed

Embase

the Cochrane Library

CNKI

Wanfang Data and VIP database till July 1 st

2021

the Stata 13.0 software was used to perform Meta-analysis. RESULTS: Totally 955 studies were retrieved

and 12 RCT including 1 458 patients were finally enrolled. Meta-analysis indicated that the negative conversion rate of sputum bacterium（OR=5.48

95%CI=3.47-8.63

P=0.000）

absorption rate of lesions（OR=3.23

95%CI=2.06-5.08

P=0.000）

closure rate of pulmonary cavities（OR=4.01

95%CI=2.64-6.09

P=0.000） and total cure rate/effective rate（OR=5.43

95%CI=2.90-10.15

P=0.000） of the observation group were higher than those of the control group

with statistically significant differences; the general incidence of adverse drug reactions of the observation group was higher than that of the control group

while the difference was not statistically significant（OR=2.41

95%CI=0.81-7.22

P=0.116）; the incidences of gastrointestinal adverse reactions（OR=1.84

95%CI=1.34-2.54

P=0.002） and peripheral nerve adverse reactions（OR=2.47

95%CI=1.46-4.17

P=0.016） of the observation group were higher than those of the control group

with statistically significant differences. CONCLUSIONS: Compared with conventional therapeutic regimen

the efficacy of combined application of linezolid in the treatment of drug-resistant tuberculosis is significantly higher

while the safety is poor

especially the adverse reactions of gastrointestinal tract and peripheral nerve.